We were delighted to talk to Geoffrey Ku (Memorial Sloan Kettering Cancer Center, New York, US) about the addition of durvalumab to induction FOLFOX and PET-directed chemoradiation for esophageal adenocarcinoma (Clinical Trial Identifier: NCT02962063). The abstract ‘Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma’ (ABSTRACT NUMBER: 226) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- Why is there a need for multimodal treatment strategies for patients with esophageal adenocarcinoma? (0:16)
- What is the rationale for the addition of durvalumab to the treatment regimen of induction FOLFOX and PET-directed chemoradiation in the treatment of esophageal adenocarcinoma? (1:06)
- Could you tell us about your recent study and its findings? (2:23)
- What will be the impact of these findings on clinical practice and what further studies are planned? (3:37)
Disclosures: Geoffrey Ku reports Research Support from Arog, AstraZeneca, BMS, Daiichi Sankyo, Merck, Oncolys, Pieris and Zymeworks, and Consulting for Apexigen, BMS, IMAB and Pieris.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
